Metabolic & Obesity Deal Benchmarks
GLP-1, diabetes, NASH/MASH, and obesity drug deal benchmarks. Benchmarks derived from 68 verified transactions.
68
Total Deals
$1.0B
Avg Upfront
6
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
38
license
11
acquisition
15
collaboration
1
option
1
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Gan & Lee Pharmaceuticals → JW Pharmaceutical Bofanglutide Injection | license | $5M | $81M | Apr 2026 |
Insilico Medicine Inc. → Eli Lilly | collaboration | $115M | $2.9B | Mar 2026 |
CSPC Pharmaceutical → AstraZeneca SYH2082 | license | $1.2B | $18.5B | Jan 2026 |
YaoPharma → Pfizer YP05002 | license | $150M | $2.1B | Dec 2025 |
Akero Therapeutics → Novo Nordisk Efruxifermin (EFX) acquisition | acquisition | $4.7B | $5.2B | Oct 2025 |
89bio → Roche Pegozafermin (MASH acquisition) | acquisition | $2.4B | $3.5B | Sep 2025 |
Lexicon Pharmaceuticals → Novo Nordisk LX9851 | license | $75M | $1.0B | Jul 2025 |
CSPC Pharmaceutical → Madrigal SYH2086 | license | $120M | $2.1B | Jul 2025 |
Boston Pharmaceuticals → GSK Efimosfermin alfa (MASH FGF21) | acquisition | $1.2B | $2.0B | May 2025 |
Scribe Therapeutics → Novo Nordisk obesity | license | $55M | $1.6B | Feb 2025 |
Benchmark Your Metabolic & Obesity Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 68 verified metabolic & obesity transactions.
Run Metabolic & Obesity Benchmark